Rules concerning safety and efficacy of drugs, etc. eased

The Korea Food and Drug Administration announced it would draft a revision on rules concerning safety and efficacy of drugs, etc., the salient points of which are as follows:

- The license procedures for new antineoplastic agents will be further simplified in a bid to allow them to be rapidly marketed in an appropriate clinical phase, including more simplified data on improved new drugs for ...